Despite the rising global incidence of central nervous system (CNS) disorders, CNS drug
development remains challenging, with high costs, long pathways to clinical use and high …

Central nervous system (CNS) diseases are among the most difficult to treat, mainly
because the vast majority of the drugs fail to cross the blood-brain barrier (BBB) or to reach …

Viruses are changing the biosensing and biomedicine landscape due to their multivalency,
orthogonal reactivities, and responsiveness to genetic modifications. As the most extensively …

Alzheimer's disease (AD) is an incurable and fatal progressive neurodegenerative disorder
associated with memory and cognition impairment. AD is one of the top medical care …

Spinal cord injury (SCI) is one of the most devastating acute diseases. Zn 2+ has been
verified plays a crucial role in SCI repair, however, how to continuously release zinc ions at …

Current chemotherapeutic strategies against various intractable cancers are futile due to
inefficient delivery, poor bioavailability, and inadequate accumulation of anticancer drugs in …

The medical emergency of COVID-19 brought to the forefront mRNA vaccine technology
where the mRNA vaccine candidates mRNA-1273 and BNT162b2 displayed superlative …

The availability of non-invasive drug delivery systems capable of efficiently transporting
bioactive molecules across the blood-brain barrier to specific cells at the injury site in the …

This article describes a new approach in targeted drug delivery to the central nervous
system (CNS) in a significant departure from the predominant systematic drug administration …

Acquired chemoresistance presents a major clinical impediment, which is an urgent problem
to be solved. Interestingly, myeloma cell leukemia‐1 (MCL‐1) and folate receptor expression …